Close
Open Nav
2019 Program to be Announced

2018 Schedule of Events

Monday, March 19, 2018

8:45am - 9:15am 

Welcome Remarks

9:15am - 10:00am

Rewarding Innovation: Challenges and Opportunities as Japan Implements Reimbursement Reform

10:15am - 6:00pm Company Presentations

10:15am - 10:55am

Next-Generation Oncology Treatments: CAR-T and Beyond

11:00am - 11:55am

Measuring the Impact of Regenerative Medicine Regulatory Reform

12:00pm - 1:25pm

Luncheon Plenary 
Globalizing Your Business Development Strategy

2:00pm - 2:55pm

Developing a National Bioventure Infrastructure and Start-Up Culture

3:00pm - 3:55pm

How Asia’s Drug Discovery Platforms Aim to be Global Players

4:00pm - 4:55pm

Market Outlook—Investor Priorities and Structuring Cross-Border Financing

6:00pm - 7:30pm

Welcome Reception

 

Tuesday, March 20, 2018

8:30am - 4:30pm

Company Presentations

9:00am - 9:55am

Lessons on Biopharma Partnerships with Universities

9:30am - 2:45pm

BIO Spark Showcase

12:00pm - 1:25pm

Luncheon Plenary
Keynote: Samantha Du

3:00pm - 3:55pm

Crafting an Effective China Strategy: Investments and Clinical Approvals


2018 Keynote Speaker:

Samantha Du, PhD, Chairman, Chief Executive Officer, Zai Lab

Samantha Du

Tuesday, March 20, 2018 
12:30 pm - 1:25 pm

Moderator: Joshua L. Berlin, Executive Director and Editor, New Ventures, BioCentury Inc.

Samantha Du, Ph.D., co-founded the company and has been the director, chairman and chief executive officer since its inception. Prior to founding Zai Lab, Dr. Du spent two years as managing director of healthcare investments at Sequoia Capital China, where she led four investments. From 2001 to 2011, Dr. Du was founder and chief executive officer of Hutchison Medi-Pharma and the co-founder and chief scientific officer of Hutchison China MediTech Limited, a Nasdaq-listed biopharmaceutical company, where she pioneered China-based global biopharmaceutical innovation by bringing five internally-discovered innovative drug candidates into clinical trials, including two global Phase III ready drug candidates. Dr. Du began her career with Pfizer in the United States in 1994, where she was involved in the development and launch of two global drugs. While at Pfizer, she was responsible for Pfizer’s global metabolic licensing program on the scientific side. She received a Ph.D. in biochemistry from the University of Cincinnati. Dr. Du has also been involved with and chaired several Chinese regulatory and government related committees.


2018 Welcome and Opening Plenary:

Monday, March 19, 8:45-10:00 am

Opening Remarks

Speaker: Jim Greenwood, President and Chief Executive Officer, Biotechnology Innovation Organization (BIO)

Welcoming Remarks

Speaker: Yoshiaki Tsukamoto, Executive Director, Japan Bioindustry Association (JBA)

Keynote Panel—Rewarding Innovation: Challenges and Opportunities as Japan Implements Reimbursement Reform

As Japan prepare to implement one of its largest changes in reimbursement policy in several years, hear from experts regarding implications for the health care ecosystem and dimensions to consider in future therapy development.

Moderator:  Joseph Damond, Executive Vice President for International Affairs, Biotechnology Innovation Organization (BIO)

Speakers:

  • Toshihiko Takeda, Director General, Pharmaceutical Bureau, MHLW*
  • Amy Jackson, PhRMA Japan Representative
  • Haruhiko Hirate, Corporate Communications & Public Affairs Officer, Takeda

2018 Educational Sessions:

Next-Generation Oncology Treatments: CAR-T and Beyond

Monday, March 19, 10:15-10:55 am

As the first personalized CAR-T treatments have received regulatory approval and start to be commercialized, and with more than 100 CAR-T clinical trials underway in Asia alone, the eagerness to improve upon the pioneer approaches is creating major cross-border deal activity and alliances to advance new therapeutic approaches.  These new approaches include allogenic CAR-T products, oncolytic viruses, natural killer (NK) cells, and other immuno-oncology mechanisms.  This session will discuss the dynamic opportunities in this space to fight cancer more effectively.

Moderator: Julia Zhen, PhD, Director, Innovation Partnership, ThermoFisher Scientific

Speakers:

  • Keigo Hanada, DVM, PhD, Executive Vice President and Chief Scientific Officer, AMBICION, Co., Ltd.
  • Christopher LeMasters, Chief Business Officer, Mirati Therapeutics
  • Li Wang, PhD, Director, Strategic Alliances, Anaeropharma Science, Inc

Measuring the Impact of Regenerative Medicine Regulatory Reform

Monday, March 19, 11:00-11:55 am

In the approximately three years since Accelerated Approval Pathways have been in place in Japan for regenerative medicine therapies, there has been a major rise in the number of these treatments being pursued there first for the purpose of clinical trials and first commercialization.  Experts who have been involved in this process can point to advantages and remaining challenges with the policy infrastructure, including ensuring access for patients to benefit from these innovative treatments.  This session will detail the practical steps necessary to consider when pursuing accelerated approvals and the benefits of such a strategy.  

Moderator: Bernard V. Fallon, Managing Director, Industry Research & Education, Biotechnology Innovation Organization (BIO)

Speakers:

  • Seiji Hirasaki, Chief Operating Officer & Head of Strategy, AnGes, Inc
  • Hardy TS Kagimoto, MD, President and Chief Executive Officer, Healios K.K.
  • Ryo Kubota, MD, PhD, Chairman, President and CEO, Kubota Pharmaceutical Holdings Co., Ltd.; Visiting Professor, School of Medicine, Keio University
  • Gil Van Bokkelen, PhD, Chairman and Chief Executive Officer, Athersys
  • John Winebarger, Founder & Managing Consultant, IDA Co., Ltd.

Globalizing Your Business Development Strategy

Monday, March 19, 12:30-1:25 pm
Luncheon Panel

With the growing harmonization of clinical trial expectations around the world, and competition to reach more patients faster via partnerships, companies are developing business development strategies that operate on a worldwide basis, even before the first approval of a new therapy.  This session will examine some benefits and challenges of conducting cross-border business development deals and the thinking that goes into negotiating national, regional, or worldwide rights, as well as alternative deal types, plus important deal-making criteria to consider in different local markets.

Moderator: Hayato Watanabe, Vice President, Tokyo, Locust Walk

Speakers:

  • Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, MediciNova
  • Sridhar Gopal Mandapati, Head Business Development, International (EEMEA - LATAM – JAPAC), AbbVie Inc.
  • Charles Stacey, MD, Chief Executive Officer, Accera Inc.

Developing a National Bioventure Infrastructure and Start-Up Culture

Monday, March 19, 2:00-2:55 pm

Countries seeking to energize the growth of their high-tech industries frequently wish to recreate the Silicon Valley system, but have difficulty achieving a critical mass of capital providers and entrepreneurs collaborating at the same pace.  Within global biotechnology, as more clinically successful new medicines get their development start via entrepreneurs instead of internal R&D, fostering a start-up culture where it does not yet exist becomes necessary for long-term industry growth.  As one infrastructure example, this session will examine how launching corporate venture arms can help change industry culture and send the right signals to invite more scientist-founders and independent venture capitalists into the sector to start new biotechs.

Moderator: Hayato Watanabe, Vice President, Tokyo, Locust Walk

Speakers:

  • Taro Inaba, Managing Partner, Remiges Ventures
  • Johnsee Lee, PhD, Chairman of Taiwan Biotech Industry Organization; Founder & CEO, Personal Genomics, Inc.
  • Kevin J. Lynch, PhD, Vice President, Search & Evaluation, AbbVie Inc.
  • Toru Seo, PhD, Senior Director, Head, External R&D Innovation Japan, Worldwide Research & Development, Pfizer Inc.

How Asia’s Drug Discovery Platforms Aim to be Global Players

Monday, March 19, 3:00-3:55 pm

With the scientific and investor interest in CRISPR and mRNA technologies as recent examples, what are the next areas on the radar of investors to emerge from academic and pre-clinical research and make major impact on therapeutic development?  This session will examine which platforms from across the region will be generating significant pipeline opportunities.

Moderator: Erin McCallister, Senior Editor and Head of Clinical Development & Market Access, BioCentury Inc.

Speakers:     

  • Shu Jen Chen, PhD, Chief Scientific Officer, ACT Genomics Co., LTD
  • Muhnho La, PhD, Director, Business Development, OliX Pharmaceuticals, Inc.
  • Jin Li, PhD, Chairman and Chief Executive Officer, HitGen Ltd    
  • Neil Lineberry, PhD, Senior Director, Strategy and Portfolio Management, Gastroenterology Therapeutic Area, Takeda Pharmaceuticals
  • Xueming Qian, PhD, Founder, Chairman & Chief Executive Officer, MabSpace Biosciences

Market Outlook—Investor Priorities and Structuring Cross-Border Financing

Monday, March 19, 4:00-4:55 pm

As the OECD predicts 3.6% global growth for 2018, the outlook for biopharma features positive signs via scientific progress but negative signs in terms of growth prospects in mature subsectors, as attention increases to climbing reimbursement trends.  Many companies are responding by seeking cross-border partners earlier in their development to compete sooner at a multinational scale, than they traditionally did based on national drug approvals.  This session will hear from deal makers and other experts on the trends they see as most influential for the year ahead in terms of equity investing.

Moderator: Bernard V. Fallon, Managing Director, Industry Research & Education, Biotechnology Innovation Organization (BIO)

Speakers:

  • Michael Chan, Senior Vice President, Hong Kong Exchanges and Clearing Limited (HKEX)
  • Shinichiro Komoto, Partner, Eight Roads
  • Damien Villeneuve, Vice President Business Development Asia-Pacific and Japan, Lupin
  • Dale Yakin, Managing Director, VelocityHealth Securities, Inc.

Lessons on Biopharma Partnerships with Universities

Tuesday, March 20, 9:00-9:30 am

With multiple recent Nobel prizes and scientific breakthroughs in the academic establishments throughout Asia, the preliminary source of biomedical innovation is in the university community.  For those discoveries to reach patients, commercial biopharma creates a variety of collaborative pathways with researchers.  This session will examine the characteristics of highly effective industry-university partnerships from experts with experiences on both sides.

Moderator: Y. Jane Tseng, PhD, Director at Drug Research Center, National Taiwan University

Speakers:

  • Richard Daly, President and Chief Executive Officer, Neuralstem, Inc.
  • Ryo Kubota, MD, PhD, Chairman, President and CEO, Kubota Pharmaceutical Holdings Co., Ltd.; Visiting Professor, School of Medicine, Keio University

BIO SPARK Showcase

Tuesday, March 20, 9:30 am-2:45 pm

The BIO SPARK Showcase aims to provide an excellent opportunity for academic researchers in the SPARK network, originally developed at Stanford University, to showcase drug development programs that are ready for partnering or venture funding.  This Showcase will feature seven presentations of cutting edge medical research from SPARK affiliates in Japan, Singapore, and Taiwan.


Crafting an Effective China Strategy: Investments and Clinical Approvals

Tuesday, March 20, 3:00-3:55 pm

With China becoming the second largest market for medicines, and its CFDA taking significant steps to make the drug approval process more appealing for both domestic and international drug development, the opportunities for companies outside the country to partner productively have increased dramatically within the past year.  This session will examine the acceleration of capital flows from China into international biotechs and from large biopharmas into China-based therapeutic development pipelines with local partners.

Moderator: Joshua L. Berlin, Executive Director and Editor, New Ventures, BioCentury Inc.

Speakers:

  • Lei Gao, PhD, General Manager, International Investment and M&A, Tasly Group and Managing Director, Tasly Capital
  • Ramon Mohanlal, EVP, Chief Medical Officer, BeyondSpring Pharmaceuticals
  • Xueming Qian, PhD, Founder, Chairman & Chief Executive Officer, MabSpace Biosciences
  • Jonathan Wang, Director of Business Development, Zai Lab
  • Tong Zhang, PhD, Managing Director, C-Bridge Capital

2018 BIO SPARK SHOWCASE AT THE BIO ASIA INTERNATIONAL CONFERENCE

 Tuesday, March 20, 2018 | 9:00 am - 3:00 pm

The BIO SPARK Showcase aims to provide an excellent opportunity for academic researchers in the SPARK network to showcase drug development programs that are ready for partnering or venture funding.

The BIO Asia International Conference is historically well attended by the business development units of major pharmaceutical companies, smaller specialty pharma/biotech companies looking to add to their pipelines, start-ups, and venture capital firms, making it the ideal setting for early-stage assets from the university setting. Academics interested in partnering will present their development candidates and also have one-on-one discussions with interested parties at the conference. 

LIST OF PRESENTATIONS

Lee Kong Chian School of Medicine, Nanyang Technological University (NTU), Singapore
Peptide Inhibitors of Kv1.3 as Therapeutics for Autoimmune Diseases
George Kanianthara Chandy
9:45-10:05 am

National Taiwan University
Development of Potential Therapeutic Agents for Irritable Bowel Syndrome
Ling-Wei Hsin
10:05-10:25 am

Oita University
Unstructured Protein: A New Approach for Drug Discovery—Anti-Rabies Virus Project
Hiroyuki Kouji
10:45-11:05 am

School of Materials Science & Engineering, Nanyang Technological University (NTU), Singapore
Better Management of Parkinson’s Disease with a Once-a-Day Formulation
Joachim Say Chye Loo
11:05-11:25 am

National Taiwan University
Novel NMDA Modulator: RS-D7
Y. Jane Tseng
11:25-11:45 am

Foresee Pharmaceuticals
Reducing Chronic Disease Burden Using Allosteric Activators of a Mitochondrial Enzyme
Wenjin Yang
1:45-2:05 pm

TMU SPARK
Development of Antibody Drug AP001 Against a Novel Tumor Marker Protein AP for Human Cancer Treatment
Yu‐Ching Le
2:05-2:25 pm

School of Biological Sciences, Nanyang Technological University (NTU), Singapore
Development of ANGPTL4-based Diagnostic Kit and Antibody Therapy for Pneumonia and Metastasis
Andrew Tan Nguan Soon
2:25-2:45 pm

*invited